Evidence map›Paper›PMID 24992504›Full record

ArticlePloS one2014

Genetic inhibition of phosphorylation of the translation initiation factor eIF2α does not block Aβ-dependent elevation of BACE1 and APP levels or reduce amyloid pathology in a mouse model of Alzheimer's disease.

Katherine R Sadleir, William A Eimer, Randal J Kaufman, Pavel Osten, Robert Vassar

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Pioglitazone Reduces β Amyloid LevelsFrontiers in aging neuroscience · 2019
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Katherine R SadleirDepartment of Cell and Molecular Biology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States of America.
William A EimerDepartment of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America.
Randal J KaufmanSanford|Burnham Medical Research Institute, La Jolla, California, United States of America.
Pavel OstenCold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States of America.
Robert VassarDepartment of Cell and Molecular Biology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States of America.
Northwestern University · USCold Spring Harbor Laboratory · USMassachusetts General Hospital · USSanford Burnham Prebys Medical Discovery Institute · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LEONIDAS C. PLATANIAS · 1993 to 2026
$153.9M
Regulation of Factor VIII SecretionR01HL052173 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAUFMAN, RANDAL J. · 1995 to 2014
$6.5M
Role of the Unfolded Protein Response in Beta CellR37DK042394 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAUFMAN, RANDAL J. · 2007 to 2016
$4.9M
Molecular Neuropathology and Mechanisms of BACE1 Elevation in Alzheimer's DiseaseR01AG030142 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI VASSAR, ROBERT J · 2007 to 2019
$3.1M
Regulation of ER stress-induced cell deathR01DK088227 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAUFMAN, RANDAL J. · 2010 to 2014
$3.1M
Unfolded Protein Response in Glucose HomeostasisR01DK042394 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAUFMAN, RANDAL J. · 2003 to 2006
$1.2M
elF2a phosphorylation in Ab42-induced BACE1 elevation in Alzheimer's diseaseF32AG033445 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SADLEIR, KATHERINE R. · 2009 to 2009
$53k
NCI NIH HHS CA060553NCI NIH HHS P30 CA060553NHLBI NIH HHS HL052173NHLBI NIH HHS R01 HL052173NIA NIH HHS 5T32AG00026NIA NIH HHS F32 AG033445NIA NIH HHS F32AG033445NIA NIH HHS R01 AG030142NIDDK NIH HHS DK042394NIDDK NIH HHS DK088227NIDDK NIH HHS R01 DK042394NIDDK NIH HHS R01 DK088227NIDDK NIH HHS R37 DK042394
6 · The paper itself

Abstract

β-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) initiates the production of β-amyloid (Aβ), the major constituent of amyloid plaques in Alzheimer's disease (AD). BACE1 is elevated ∼2-3 fold in AD brain and is concentrated in dystrophic neurites near plaques, suggesting BACE1 elevation is Aβ-dependent. Previously, we showed that phosphorylation of the translation initiation factor eIF2α de-represses translation of BACE1 mRNA following stress such as energy deprivation. We hypothesized that stress induced by Aβ might increase BACE1 levels by the same translational mechanism involving eIF2α phosphorylation. To test this hypothesis, we used three different genetic strategies to determine the effects of reducing eIF2α phosphorylation on Aβ-dependent BACE1 elevation in vitro and in vivo: 1) a two-vector adeno-associated virus (AAV) system to express constitutively active GADD34, the regulatory subunit of PP1c eIF2α phosphatase; 2) a non-phosphorylatable eIF2α S51A knockin mutation; 3) a BACE1-YFP transgene lacking the BACE1 mRNA 5' untranslated region (UTR) required for eIF2α translational regulation. The first two strategies were used in primary neurons and 5XFAD transgenic mice, while the third strategy was employed only in 5XFAD mice. Despite very effective reduction of eIF2α phosphorylation in both primary neurons and 5XFAD brains, or elimination of eIF2α-mediated regulation of BACE1-YFP mRNA translation in 5XFAD brains, Aβ-dependent BACE1 elevation was not decreased. Additionally, robust inhibition of eIF2α phosphorylation did not block Aβ-dependent APP elevation in primary neurons, nor did it reduce amyloid pathology in 5XFAD mice. We conclude that amyloid-associated BACE1 elevation is not caused by translational de-repression via eIF2α phosphorylation, but instead appears to involve a post-translational mechanism. These definitive genetic results exclude a role for eIF2α phosphorylation in Aβ-dependent BACE1 and APP elevation. We suggest a vicious pathogenic cycle wherein Aβ42 toxicity induces peri-plaque BACE1 and APP accumulation in dystrophic neurites leading to exacerbated Aβ production and plaque progression.

Indexed as

5' Untranslated RegionsAlzheimer DiseaseAmino Acid SubstitutionAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesAnimalsBrainCells, CulturedDisease Models, AnimalEukaryotic Initiation Factor-2Gene Knock-In TechniquesMaleMiceMice, Inbred C57BLMice, Transgenic5' Untranslated RegionsAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesEukaryotic Initiation Factor-2Ppp1r15a protein, mouseProtein Phosphatase 1

Identifiers

PMID24992504
PMCPMC4081565
OpenAlexW2086879787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.